Abstract
When Nature Reviews Urology launched in 2004, the field of urology was vastly different to that which we work in today, and the past 10 years have seen the field change immensely. As a specialty on the forefront of cutting-edge innovation, urologists are often the first to embrace new technologies and ideas. In this Viewpoint, members of the Nature Reviews Urology advisory board were asked what they thought was the most important change, issue or innovation in urology in the past 10 years, and what they expected to be the most important in the next decade. Here are their opinions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bochinski, D. et al. The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. BJU Int. 94, 904–909 (2004).
Yiou, R. et al. Intra-cavernous injection of bone marrow stem cells is well tolerated and improve erectile function in patients with post-prostatectomy erectile dysfunction: Preliminary results of a phase I-II clinical trial. Abstract 599. Presented at the 29th Annual EAU Congress (2014).
Wilt, T. J. et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203–213 (2012).
Bul, M. et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur. Urol. 63, 597–603 (2013).
Sridhar, A. N. et al. Image-guided robotic interventions for prostate cancer. Nat. Rev. Urol. 10, 452–462 (2013).
Lawrentschuk, N. & Klotz, L. Active surveillance for low-risk prostate cancer: an update. Nat. Rev. Urol. 8, 312–320 (2011).
Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011).
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
Centers for Disease Control and Prevention. Assisted Reproductive Technology [online], (2014).
Baillargeon, J. et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern. Med. 173, 1465–1466 (2013).
International Telecommunication Union. The world in 2013: ICT facts and figures [online], (2014).
Agarwal, A. et al. Effect of cell phone usage on semen analysis in men attending infertility clinic: an observational study. Fertil. Steril. 89, 124–128 (2008).
US Food and Drug Administration. Outpatient Prescription Opioid Utilization in the U. S. Years 2000–2009 [online], (2014).
Fronczak, C. M., Kim, E. D. & Barqawi, A. B. The insults of illicit drug use on male fertility. J. Androl. 33, 515–528 (2012).
Barazani, Y. et al. Lifestyle, environment, and reproductive health. Urol. Clin. N. Am. 41, 55–66 (2013).
Moyer, V. A. U.S. Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120–134 (2012).
Barry, M. J., Gallagher, P. M., Skinner, J. S. & Fowler, F. J. Jr. Adverse effects of robotic-assisted laparoscopic versus open radical retropubic prostatectomy among a nationwide sample of Medicare-age men. J. Clin. Oncol. 30, 513–513 (2012).
Tewari, A. et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur. Urol. 62, 1–15 (2012).
Gandaglia, G. et al. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J. Clin. Oncol. 32, 1419–1426 (2014).
Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).
de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).
Attard, G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742–3748 (2008).
Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).
Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).
Stenzl, A. et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur. Urol. 59, 1009–1018 (2011).
Acknowledgements
H.N. would like to thank Doron Stember for his assistance with his contribution to this article.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
H. G. declares that he is a member of the speakers' bureau for Allergan, Medtronic and Uroplasty, and that he has acted as a consultant for Allergan, Astellas, Medtronic and Uroplasty. P.S. declares that he is a scientific advisor to OPKO Diagnostics, who are developing a commercial assay for the 4KScore® developed at Memorial Sloan–Kettering. A.S. declares that has acted as a consultant for Alere, and as a speaker and consultant for Ipsen and Janssen. His institution receives research grants from Amgen, Immatics Biotechnologies GmbH, Karl Storz and Novartis, and is involved in clinical studies with Bayer, CureVac, Immatics Biotechnologies GmbH and Johnson & Johnson. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Albersen, M., Cartwright, R., Choyke, P. et al. Looking forward, looking back—10 years in urology. Nat Rev Urol 11, 649–655 (2014). https://doi.org/10.1038/nrurol.2014.263
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.263
